Cytosorbents Corp(CTSO)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Cytosorbents Corp (CTSO) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CTSO at 17.6/100 on a 32-signal composite quality model, placing it at rank #2,825 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (4.6) and revenue scale (6.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 19.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Cytosorbents Corp reports quarterly revenue of $9.6M, net income of $-4.4M, an operating margin of -27.4%. Top institutional holders of CTSO by reported 13-F value include AVENIR, Neuberger Berman Group, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. CTSO trades on the Nasdaq exchange and files with the SEC under CIK 1175151. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CTSO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cytosorbents Corp directly from SEC EDGAR.